title: The relationship between hypomagnesemia, metformin therapy and cardiovascular disease complicating type 2 diabetes: the Fremantle Diabetes Study.
abstract: BACKGROUND
  Low serum magnesium concentrations have been associated with cardiovascular disease risk and outcomes in some general population studies but there are no equivalent studies in diabetes. Metformin may have cardiovascular benefits beyond blood glucose lowering in type 2 diabetes but its association with hypomagnesemia appears paradoxical. The aim of this study was to examine relationships between metformin therapy, magnesium homoeostasis and cardiovascular disease in well-characterized type 2 patients from the community.
  
  
  RESULTS
  We studied 940 non-insulin-treated patients (mean ± SD age 63.4 ± 11.6 years, 49.0% males) from the longitudinal observational Fremantle Diabetes Study Phase I (FDS1) who were followed for 12.3 ± 5.3 years. Baseline serum magnesium was measured using stored sera. Multivariate methods were used to determine associates of prevalent and incident coronary heart disease (CHD) and cerebrovascular disease (CVD) as ascertained from self-report and linked morbidity/mortality databases. 19% of patients were hypomagnesemic (serum magnesium <0.70 mmol/L). Patients on metformin, alone or combined with a sulfonylurea, had lower serum magnesium concentrations than those on diet alone (P<0.05). There were no independent associations between serum magnesium or metformin therapy and either CHD or CVD at baseline. Incident CVD, but not CHD, was independently and inversely associated with serum magnesium (hazard ratio (95% CI) 0.28 (0.11-0.74); P=0.010), but metformin therapy was not a significant variable in these models.
  
  
  CONCLUSIONS
  Since hypomagnesemia appears to be an independent risk factor for CVD complicating type 2 diabetes, the value of replacement therapy should be investigated further, especially in patients at high CVD risk.
authors.affiliation: University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, Fremantle, Western Australia, Australia.
authors.forename: Kirsten E
authors.initials: KE
authors.lastname: Peters
authors.forename: S A Paul
authors.initials: SA
authors.lastname: Chubb
authors.forename: Wendy A
authors.initials: WA
authors.lastname: Davis
authors.forename: Timothy M E
authors.initials: TM
authors.lastname: Davis
mesh_terms: D000328:Adult; D002318:Cardiovascular Diseases / Q000150:complications*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008274:Magnesium / Q000097:blood*; D008297:Male; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged
chemical_list: D007004:Hypoglycemic Agents; D008687:Metformin; D008274:Magnesium
references.citation: BMJ. 2010 May 20;340:c2181
references.pmid: 20488910
references.citation: Clin Chim Acta. 1979 Jul 16;95(2):235-42
references.pmid: 527222
references.citation: PLoS Med. 2012;9(4):e1001204
references.pmid: 22509138
references.citation: Biol Trace Elem Res. 2010 May;134(2):119-29
references.pmid: 19629403
references.citation: Clin Chem. 1985 Feb;31(2):244-6
references.pmid: 3967355
references.citation: Lancet. 1998 Sep 12;352(9131):854-65
references.pmid: 9742977
references.citation: J Clin Pathol. 1988 Sep;41(9):933-5
references.pmid: 3192752
references.citation: Int J Epidemiol. 2013 Apr;42(2):412-21
references.pmid: 22544845
references.citation: Am J Epidemiol. 2009 Jun 15;169(12):1437-44
references.pmid: 19372211
references.citation: Am Heart J. 2010 Oct;160(4):715-20
references.pmid: 20934566
references.citation: Diabetes Obes Metab. 2011 Mar;13(3):221-8
references.pmid: 21205121
references.citation: Clin Sci (Lond). 2012 Jul;123(1):1-14
references.pmid: 22409531
references.citation: Kidney Int. 1986 Feb;29(2):563-71
references.pmid: 2871216
references.citation: Am Heart J. 1998 Sep;136(3):480-90
references.pmid: 9736141
references.citation: Magnes Res. 2007 Jun;20(2):107-29
references.pmid: 18062585
references.citation: Cases J. 2009 Oct 16;2:156
references.pmid: 19946527
references.citation: Magnes Res. 2011 Dec;24(4):163-80
references.pmid: 22064327
references.citation: Diabetes Obes Metab. 2010 Sep;12(9):757-65
references.pmid: 20649627
references.citation: J Lab Clin Med. 1953 Feb;41(2):215-9
references.pmid: 13035253
references.citation: Swiss Med Wkly. 2003 May 17;133(19-20):289-92
references.pmid: 12844272
references.citation: Aust Health Rev. 2008 Nov;32(4):766-77
references.pmid: 18980573
references.citation: Atherosclerosis. 2011 Nov;219(1):280-4
references.pmid: 21703623
references.citation: Diabet Med. 1995 Aug;12(8):664-9
references.pmid: 7587003
references.citation: Cell Mol Biol Res. 1995;41(5):347-59
references.pmid: 8867781
references.citation: Diabetes Care. 2012 Jun;35(6):1364-79
references.pmid: 22517736
references.citation: J Clin Epidemiol. 1995 Jul;48(7):927-40
references.pmid: 7782801
references.citation: J Am Acad Nurse Pract. 2009 Dec;21(12):651-7
references.pmid: 19958415
references.citation: Stroke. 2004 Jan;35(1):22-7
references.pmid: 14657448
references.citation: Am J Clin Nutr. 2012 Feb;95(2):362-6
references.pmid: 22205313
references.citation: J Gen Intern Med. 2001 Mar;16(3):168-75
references.pmid: 11318912
references.citation: Diabetes Care. 2006 Mar;29(3):575-80
references.pmid: 16505509
references.citation: Magnes Res. 1997 Dec;10(4):315-20
references.pmid: 9513927
references.citation: Ann Nutr Metab. 2012;61(2):102-10
references.pmid: 22907037
references.citation: N Engl J Med. 2008 Oct 9;359(15):1577-89
references.pmid: 18784090
references.citation: Biol Trace Elem Res. 2011 Jul;142(1):36-46
references.pmid: 20567934
references.citation: Biol Trace Elem Res. 2007 Winter;120(1-3):102-9
references.pmid: 17916960
references.citation: Curr Opin Lipidol. 2008 Feb;19(1):50-6
references.pmid: 18196987